Clinical Trial Update: Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer [NA]

View source ↗

Summary

The study evaluating neoadjuvant FOLFOX plus bevacizumab for locally advanced colon cancer was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Colon Cancer | NA | Status: TERMINATED | Results posted: 2015-04-15